These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12731484)

  • 1. New treatment option emerges for newly diagnosed multiple myeloma.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Nov; 13(23):10, 12. PubMed ID: 12731484
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
    Huston A; Brown J; Roodman GD
    Exp Hematol; 2006 Dec; 34(12):1616. PubMed ID: 17157156
    [No Abstract]   [Full Text] [Related]  

  • 3. Thalidomide and dexamethasone: therapy for multiple myeloma.
    Kumar S; Rajkumar SV
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide and venous thrombosis in multiple myeloma.
    Rajkumar SV; Blood E
    N Engl J Med; 2006 May; 354(19):2079-80. PubMed ID: 16696148
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of thalidomide in previously untreated patients with multiple myeloma.
    Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide and venous thrombosis in multiple myeloma.
    Knight R; DeLap RJ; Zeldis JB
    N Engl J Med; 2006 May; 354(19):2079-80. PubMed ID: 16687729
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
    Sviggum HP; Davis MD; Rajkumar SV; Dispenzieri A
    Arch Dermatol; 2006 Oct; 142(10):1298-302. PubMed ID: 17043184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.
    Boga C; Ozdogu H; Yeral M; Kizilkilic E; Tamer L
    J Support Oncol; 2007 Jun; 5(6):256. PubMed ID: 17624049
    [No Abstract]   [Full Text] [Related]  

  • 13. Thalidomide and dexamethasone for newly diagnosed multiple myeloma: is this really the standard of care?
    Nabhan C; Bitran JD
    J Clin Oncol; 2006 Jun; 24(18):2967-8; author reply 2968-9. PubMed ID: 16782938
    [No Abstract]   [Full Text] [Related]  

  • 14. Thalidomide in the treatment of multiple myeloma.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
    Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
    Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thalidomide treatment in multiple myeloma].
    Hattori Y
    Rinsho Ketsueki; 2003 May; 44(5):302-12. PubMed ID: 12822404
    [No Abstract]   [Full Text] [Related]  

  • 18. [Guideline for the appropriate use of thalidomide in the treatment of multiple myeloma].
    Rinsho Ketsueki; 2005 Jan; 46(1):22-42. PubMed ID: 16724412
    [No Abstract]   [Full Text] [Related]  

  • 19. Eastern Cooperative Oncology Group E1A00: phase III randomized study of dexamethasone with or without thalidomide in patients with newly diagnosed multiple myeloma.
    Greipp PR
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):188-9. PubMed ID: 16224404
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
    Rajkumar SV; Blood E; Vesole D; Fonseca R; Greipp PR;
    J Clin Oncol; 2006 Jan; 24(3):431-6. PubMed ID: 16365178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.